RESEARCH COLLABORATION AGREEMENT BY AND BETWEEN NAUREX INC. AND APTINYX INC. DATED AS OF JULY 24, 2015Research and Collaboration Agreement • May 23rd, 2018 • Aptinyx Inc. • Pharmaceutical preparations • New York
This Research Collaboration Agreement (this “Agreement”), dated as of July 24, 2015 (the “Execution Date”), is entered into by and between Naurex Inc., a Delaware corporation (the “Company”) and Aptinyx Inc., a Delaware corporation (“SpinCo”). The Company and SpinCo are each referred to herein by name or as a “Party” or, collectively, as “Parties”.
AMENDED AND RESTATED RESEARCH AND COLLABORATION AGREEMENT by and among Eli Lilly and Company and ProQR Therapeutics N.V. and ProQR Therapeutics VIII B.V. AMENDED AND RESTATED RESEARCH AND COLLABORATION AGREEMENTResearch and Collaboration Agreement • December 23rd, 2022 • ProQR Therapeutics N.V. • Pharmaceutical preparations • New York
This Amended and Restated Research and Collaboration Agreement (“Agreement”) entered into as of December 21st, 2022 (the “A&R Effective Date”), by and among ProQR Therapeutics N.V., a company organized and existing under the laws of the Netherlands, having its principal place of business at Zernikedreef 9, 2333 CK Leiden, The Netherlands, and ProQR Therapeutics VIII B.V., a company organized and existing under the laws of the Netherlands, having its principal place of business at Zernikedreef 9, 2333 CK Leiden, the Netherlands, (such entities, collectively, “ProQR”), and Eli Lilly and Company, a corporation organized and existing under the laws of Indiana, with its principal business office located at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A. (“Lilly”), amends, restates and supersedes in its entirety (except as expressly set forth herein), that certain Research and Collaboration Agreement, entered into as of September 3rd, 2021 (the “Effective Date”), by and among the
RESEARCH AND COLLABORATION AGREEMENTResearch and Collaboration Agreement • March 13th, 2012 • Champions Oncology, Inc. • Biological products, (no disgnostic substances) • Delaware
This Research and Collaboration Agreement (“Agreement”) is effective as of March 16, 2011 (the “Effective Date”) between Cephalon, Inc., a Delaware corporation with offices located at 41 Moores Road, Frazer, Pennsylvania 19355 (“Cephalon”) and Champions Biotechnology, Inc., a Delaware corporation with offices located at 855 N. Wolfe Street, Suite 619, Baltimore, Maryland 21205 (“Champions”).
PURSUANT TO ITEM 601(B)(2)(II) OF REGULATION S-K, CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AS [****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...Research and Collaboration Agreement • February 3rd, 2022 • RenovaCare, Inc. • Surgical & medical instruments & apparatus • New York
Research and Collaboration Agreement is made as of the 28 day of January, 2022 (the “Effective Date”) by and between RenovaCare Inc, a Nevada corporation, having an executive office is at 9375 E. Shea Blvd., Suite 107-A, Scottsdale, AZ 85260 (USA) (the “RCAR”) and HistoCell S.L., a regenerative medicine company, having offices at Parque Tecnologico 801. 2nd Floor, 48160 – Derio (Bezkaia) Spain, (“HistoCell”) (this “Agreement”); each of RCAR and HistoCell are also referred to individually herein as a “Party” or collectively as the “Parties.”
Sponsored Research and Collaboration AgreementResearch and Collaboration Agreement • September 21st, 2017 • Ontario
WHEREAS the Parties wish to undertake a research project entitled “< insert title >”as described in the attached Appendix “A” (the “Project”);
RESEARCH AND COLLABORATION AGREEMENT between TEVA PHARMACEUTICAL INDUSTRIES LIMITED and COCRYSTAL DISCOVERY, INC. Dated as of September 13, 2011Research and Collaboration Agreement • August 14th, 2014 • Cocrystal Pharma, Inc. • Pharmaceutical preparations • New York
THIS RESEARCH AND COLLABORATION AGREEMENT (the “Agreement”) is made and entered into as of September 13, 2011 (“Effective Date”) by and between:
AMENDMENT #1 TO THE SECOND AMENDMENT TO THE TECHNOLOGY, LICENSE, DEVELOPMENT, RESEARCH AND COLLABORATION AGREEMENTResearch and Collaboration Agreement • August 10th, 2015 • Amyris, Inc. • Industrial organic chemicals
This Amendment #1 to the Second Amendment to the Technology, License, Development, Research and Collaboration Agreement (the “Amendment #1”) is entered as of April 1, 2015 by and between:
Research and Collaboration AgreementResearch and Collaboration Agreement • May 4th, 2023
[«AgreementPartyName_1»], a corporation incorporated under the laws of [Canada][Ontario] having its administrative offices at [insert address] (“Company”)
RESEARCH AND COLLABORATION AGREEMENTResearch and Collaboration Agreement • August 10th, 2023 • Verve Therapeutics, Inc. • Pharmaceutical preparations • New York
This Research and Collaboration Agreement (this “Agreement”) is made and entered into as of June 14, 2023 (the “Execution Date”) by and between Verve Therapeutics, Inc., a Delaware corporation (“Verve”), and Eli Lilly and Company, an Indiana corporation (“Lilly”). Verve and Lilly are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Dated July 11th 2014 BIOMICS BIOTECH CO., LTD. and BENITEC BIOPHARMA LIMITED RESEARCH AND COLLABORATION AGREEMENT- OVERALL PROJECT FRANCIS ABOURIZK LIGHTOWLERS Commercial & Technology Lawyers Level 16 MELBOURNE VIC 3000 Tel: (03) 9642 2252 Fax: (03)...Research and Collaboration Agreement • June 22nd, 2015 • Benitec Biopharma LTD/ADR • Pharmaceutical preparations
Biomics Biotech Co., Ltd. (Chinese Registration Number 320600400015467) of 76 Changxing Rd, Economic & Technology Development Area, Nantong 226016 P.R. China (“Biomics”)
